Amazon now requires cGMP proof for more supplement factories than FDA inspects. The bill isn't landing where everyone expected.
On March 31, Amazon started deactivating supplement listings whose copy did not match the Supplement Facts panel. That landed on top of December’s expansion, which extended third-party cGMP verification from a handful of high-risk categories to every supplement sold on Amazon US. Some agency and trade headlines in January predicted thousands of listings would disappear.
One month in, there is no public count of delistings, and no public sign of brands leaving the platform. That does not mean nothing happened. It means the cost is landing somewhere less visible than the headlines expected. This report is about who is paying for Amazon’s new rulebook — and why the answer is SKUs, not brands. (For what actually triggers a suppression, see our suppression taxonomy; this report does not repeat it.)
The rulebook was built in layers.
| Date | What changed |
|---|---|
| 2020 | Product images and certificates of analysis required |
| April 2024 | Third-party verification for 3 high-risk categories, through 3 approved testing firms (NSF, Eurofins, UL), renewed annually |
| By December 2025 | High-risk list grows to 5: sexual enhancement, weight management, bodybuilding, sports nutrition, joint health |
| December 2025 | cGMP verification for all supplements announced, phased in seller by seller with 90-day windows; Compliance Fast-Track for brands already certified by BSCG, Clean Label Project, GRMA, Informed, NSF or USP |
| January 14, 2026 | Amazon emails sellers: listings must match the Supplement Facts panel |
| March 31, 2026 | Deactivation for mismatched listings begins |
The two layers do different jobs. The high-risk layer, in place since 2024, tests products — for label claims, contaminants and undeclared drug ingredients. The 2026 expansion mainly verifies facilities: proof from an accredited third party that the manufacturing site meets cGMP. Amazon’s January notice, as reported by PPC Land, adds the listing layer: no raw-herb weights presented as extract weights (its own example is “10,000mg” of raw herb for a 500mg extract), no weights without an ingredient name and a portion, and no copy that implies more potency than the panel shows.
Compare that with FDA’s reach. FDA inspected 600 supplement facilities in fiscal 2024 — 510 domestic, 90 foreign — which the agency’s own supplement office describes as about 5% of known facilities. In fiscal 2023, 48% of inspections ended with a Form 483. FDA also cut roughly 3,500 staff agency-wide in last year’s restructuring, about 170 of them from inspections. On coverage alone, Amazon is moving to cGMP proof behind every supplement it sells. Notably, it will not accept an FDA inspection as that proof, according to Epstein Becker Green’s analysis.
On cost, the public benchmarks are mostly from the 2024 high-risk regime. A contract manufacturer told NutraIngredients in 2024 that a customer spending about $650 on a product to sell on Amazon would need $2,000–2,500 at minimum for testing. NOW Foods put its cost at over $100,000 a year for about 50 products. Five Star Commerce, an Amazon agency, quoted new third-party testing at roughly $250–1,000 per product in April (most quotes $500–1,000), validation of existing ISO 17025 data at $80–120, and high-risk testing higher still — with “bracketing” allowing one test set to cover several ASINs that share a formula and facility.
FDA’s capacity gap and Amazon’s own exposure. FDA inspects a small fraction of supplement facilities each year. In December 2023, it sent Amazon a warning letter over “energy enhancing” products allegedly containing undeclared sildenafil and tadalafil. Amazon’s response has been to stop trusting documents sellers upload. Since 2024, its line has been that it will not accept documents directly from sellers; verification flows from the testing firm to Amazon.
The listing is now treated as a label. “Anything that has a claim about the product has to exactly match the supplement facts panel,” compliance consultant Justin Schumacher told NutraIngredients in March. Enforcement is reported to be largely automated; Amazon has not confirmed how. Asa Waldstein’s early read in Vitafoods Insights is that “this seems to be based on keywords rather than context” — which means compliant copy can get caught too.
Breadth, not depth. Outside the five high-risk categories, the default check is a facility certificate plus a match between the listing text and the panel. Neither tests what is in the bottle. Even inside the high-risk layer, analytical chemist James Kababick has pointed out that the drug screens cover “a small handful” of the hundreds of known steroid and PDE5 analogues. NOW’s CEO Jim Emme said in December that the program “seems to only work with the honest brands.” Amazon has become the broadest private gatekeeper for US supplements. It has not become the strictest.
The gate is widening. In April 2024 there were three approved testing firms, which AHPA called “gatekeepers.” By April, one agency’s reading of Amazon’s provider list included Certified Laboratories, Cotecna, Eurofins, Intertek, Mérieux NutriSciences, NSF, SGS and UL, and the Fast-Track route lets already-certified manufacturers carry the facility layer for their customers. More providers means more price competition and less of a queue.
They choose manufacturers already inside a certification program. If your contract manufacturer is NSF, USP or GRMA certified, Fast-Track may let Amazon validate the facility layer from existing certification data. It does not cover category-specific product testing. The cheapest compliance decision is the one made at the manufacturer, not at the listing.
They bracket tests and cut slow variants. Testing costs are fixed per facility and per test. Brands spreading one test set across ASINs with the same formula are paying a fraction of what brands testing every flavor separately pay. And some variants are simply not worth verifying.
They rewrote botanical copy around the panel number. Raw-equivalent milligrams were the first target in Amazon’s notice. The brands handling it well moved the commercial story to standardization — percent actives, extract ratio stated alongside the panel weight — rather than a bigger number that does not match the label.
They treat the listing as a regulated document. One source of truth, from the Supplement Facts panel to every field on the detail page, with images showing the full label and lot code.
If you run a supplement brand doing $1M–$15M on Amazon, three adjustments are worth making now.
Budget compliance per SKU, per year — and look hard at the tail. As illustrative arithmetic: a $500 annual test spread across 30,000 units is two cents a unit. Across 300 units, it is $1.67. At the 2024 high-risk floor of around $2,000, a 300-unit SKU carries $6.67 a unit. The cost is regressive by SKU velocity, not by brand size. That points to SKU rationalization, not small brands leaving the platform.
If you sell in a high-risk category, price annual testing into cost of goods. It renews every year. It is not a one-off.
Expect fewer long-tail listings and less number inflation. Brands that already labeled honestly lose less in side-by-side comparisons as raw-equivalent claims disappear. The fraud problem is not solved — and competitor-led testing of rival products is likely to continue.
Watch two things next. Whether Amazon extends adulterant screening beyond the five high-risk categories — the list already grew from three in 2024 to five by late 2025. And how quickly erroneous flags get fixed: one consultant, Luca Bucchini, already reports difficulty reaching qualified Amazon staff to reverse mistaken deactivations.
If you want to see which of your listings no longer match your Supplement Facts panel, Verid8 scans titles, bullets and images against Amazon’s supplement rules — start with a free listing scan. If a listing is already down, start here. For a catalog-wide review of claims, certificates and margin, order an audit.
Keep reading: What actually triggers a suppression · Case file: a claim-language suppression, rescued · ACoS is the wrong metric for supplement brands
Market Analyses are published the first Tuesday of every month. Figures as of May 5, 2026. Sources: Amazon seller notices as reported by trade press, FDA via SupplySide, Epstein Becker Green, NutraIngredients, Vitafoods Insights and named agency quotes; per-unit figures are illustrative arithmetic. This report is market analysis, not legal advice. The next report looks at creatine — and the buyer who changed it.
Subscribe to get every report in your inbox — published the first Tuesday of every month.